Recipharm Pharmaceutical Development is pleased to announce the appointment of Dr Hans Lennernäs to the company's Board of Directors.

Dr. Hans Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery; controlling a budget of €24.5 million.

His research responsibilities and remit are focused on membrane transport and metabolism of drugs/metabolites in the gastrointestinal tract, hepatobiliary system and cancer tissues.

In addition to his academic achievements, Dr Lennernäs has built an entrepreneurial reputation by cofounding several companies including DuoCort Pharma, and Lidds, whilst investing in a number of patents.